ABSTRACT
NTRK gene fusions are oncogenic drivers of various paediatric and adult tumor types. The fusion proteins encoded by these fusion genes have tropomyosin related kinase (TRK) tyrosine kinase domains, which provides novel targets for tumor targeted therapy. The treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rate (>75%), regardless of tumor histology. The first-generation TRK inhibitors are well tolerated by most patients. Chronic use of TRK inhibitors can lead to secondary resistance, and the resistance is mediated by the acquisition of NTRK kinase domain mutations. Fortunately, certain resistance mutations can be overcome by second-generation TRK inhibitors, including LOXO-195 and TPX-0005 that are being explored in clinical trials. As for its good efficacy and safety, NTRK targeted therapy is a new choice for the treatment of relapsed refractory solid tumors with NTRK fusion.
ABSTRACT
Objective To analysis clinical effect of Diyu Shengbai tablets combined with granulocyte colony stimulating factor on cancer related fatigue syndrome.Methods II-VI primary cancer 60 patients from January 2011 to December 2013 were admitted to department of internal medicine, Fourth Hospital of Hebei Medical University,and randomly divided into two groups.Control goup(n=30)were treated with granulocyte colony stimulating factor(G-CSF).Experimental group(n=30)were treated with Diyu Shengbai tablets and G-CSF.Results After chemotherapy, ratio of patients in the experimental group appeared fatigue syndrome and changes in leukocyte was significantly lower than that of control group, the difference was statistically significant ( P <0.05 ) . Conclusion Diyu Shengbai tablets combined with G-CSF have better clinical efficacy for leukopenia caused by tumor chemotherapy, the symptom of fatigue also can improve significantly.
ABSTRACT
ObjectiveTo find out the risk factors and the incidence of lithiasis. MethodsA questionnaire was formulated by the National Biliary Surgical Group. It was sent to the medical staff of all levels of hospitals in the Zunyi Region, Guizhou to fill in on surgically proven cases of cholelithiasis. The clinical data were collected and analyzed using SPSS 13.0. ResultFor lithiasis, the gender ratio was 1∶ 1.78; the peak age was 41-year and 51-year respectively. The proportion of cholecystolithiasis (n =4456 ; 86.76 ％) and choledocholithiasis (n =554;10.79 ％ ) was comparatively higher than in other regions in China. ConclusionsThe commonest type of lithiasis in Zunyi was cholecystolithiasis. There was an increasing tendency for lithiasis to develop in young people. Lithiasis was closely associated with factors such as gender, food and occupation.
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical effect, CT image changes and side-effects of percutaneous microwave coagulation therapy for lung cancer.</p><p><b>METHODS</b>CT-guided percutaneous puncture was performed using a needle mono-pole microwave antenna with 65W, 2 450 MHz microwave delivered in 60 seconds to 20 peripheral lung cancer patients, including 8 suffering from primary lung cancer and 12 metastatic lung cancer (totally 28 lesions).</p><p><b>RESULTS</b>Sixteen patients were alive after having been followed-up for 3 approximately 24 months. All patients showed nodules decreased in size. Diminution of over 50% was observed in 13 nodules and 3, completely disappeared. The overall response rate was 57.1%. Ellipsoid shadow 3.5 cm x 2.5 cm across was observed by CT in lesions immediately after coagulation. Gasification within the coagulated area was observed in a week with a high density in the peripheral region. Consolidation was observed in 3 months and the lesion disappeared 1 year later. Complete tumor necrosis was proved by biopsy. No side-effects or complications were observed.</p><p><b>CONCLUSION</b>Percutaneous microwave coagulation therapy is a new safe treatment for lung cancer, giving marked effect but minimum trauma.</p>